Access to modern contraception can save lives. About one in three maternal deaths could be avoided by delaying motherhood, spacing births, preventing unintended pregnancies, and avoiding unsafely performed abortions.
Injectable contraceptives are among the world’s most popular methods for preventing pregnancy, offering women safe and effective protection, convenience, and privacy. Until now, however, they have not been widely available outside clinic settings. Sayana® Press, a lower-dose formulation and presentation of Depo-Provera®, offers the potential to improve contraceptive access for women worldwide.
Pfizer Inc., the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF) partnered to expand access to Pfizer’s injectable contraceptive, Sayana® Press, for women most in need in 69 of the world’s poorest countries . Through this collaboration of organizations from the public and private sectors, Sayana® Press will be sold for US $1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
|Location||Worldwide, Uganda, Honduras, Hong Kong, Howland, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Isle of Man, Israel, Italy, Niger, Nigeria, Senegal|
|Value||USD 29 Million|